Abstract Library

#3070 Activity and Safety of Avelumab in Merkel Cell Carcinoma: Our Experience

Introduction: Merkel cell carcinoma (MCC) is an aggressive neuroendocrine carcinoma of the skin. The use of checkpoint inhibitors has shown good results in the treatment of advanced MCC. Avelumab is a PD-L1 inhibitor able to prevent the inactivation of the T lymphocytes. We report a serie of consecutive MCC cases treated with Avelumab in two centres

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Giuffrida D

Authors: Puliafito I, Sciacca D, Bonasera A, Blanco G, Iacono F,

Keywords: mcc, avelumab, activity, safety,

#2960 Epidemiological Characteristics of Neuroendocrine Tumors: A Retrospective Analysis of a Single Centre

Introduction: Neuroendocrine tumors (NETs) are a small heterogeneous group of cancers, developing from the neuroendocrine system. NETs may include functional or non-functional tumors; moreover, they may be familial and have further associated tumors.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Giuffrida D

Authors: Puliafito I, Blanco G, Sciacca D, Colarossi C, Leotta E,

Keywords: neuroendocrine, tumors, our, retrospective, analysis,

#2232 Role of Interval Reduction of Somatostatin Analogs in Patients with Progressive Neuroendocrine Tumors: Our Experience

Introduction: Interval reduction of somatostatin analogs (SSAs) is a possibly strategy for elderly patients with progressive metastatic neuroendocrine tumors (NETs). Patients with diagnosis of NET are >75 years old in the 25% of cases. No randomized studies are available to evaluate efficacy of this treatment schedule.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Puliafito I, Prestifilippo A, Colarossi C, Giuffrida P, Castorina L,

Keywords: somatostatin, analogs, interval, reduction, experience, elderly,

#2151 Therapeutic Efficacy of Platinum/Etoposide Regimens in the Treatment of Advanced Poor Differentiated Neuroendocrine Carcinomas of the Lung: A Retrospective Analysis

Introduction: Advanced neuroendocrine carcinomas (NEC) of the lung are associated with a dismal prognosis and are commonly treated with platinum/etoposide (P/E) regimens. However, few studies evaluated their impact in lung NEC and it is still unclear whether the outcome of such patients (pts) has been improved over the past years (yrs).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Giuffrida D

Authors: Giuffrida D, Chillari F, Blanco G, Russo A, Franchina T,

Keywords: neuroendocrine carcinoma, lung, platinum-etoposide, LCNEC, SCLC, chemotherapy,

#383 Everolimus and Octreotide LAR in Neuroendocrine Tumors: An I.T.M.O. (Italian Trials in Medical Oncology) Group Study

Introduction: Everolimus has shown antitumor activity in pancreatic neuroendocrine tumors (NETs) and it seems to work synergistically with octreotide.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Bajetta E, Catena L, Biondani P, Fazio N, Giuffrida D,

Keywords: Everolimus, Octreotide LAR, neuroendocrine tumors,